Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 92 Breast Neoplasms 69 Prostatic Neoplasms 33 Triple Negative Breast Neoplasms 32 Neoplasms 26 Fallopian Tube Neoplasms 25 Neoplasm Metastasis 21 Endometrial Neoplasms 19 Pancreatic Neoplasms 18 Small Cell Lung Carcinoma 13 Carcinoma, Ovarian Epithelial 12 Carcinoma, Non-Small-Cell Lung 10 Stomach Neoplasms 9 Sarcoma 9 Recurrence 9 Lung Neoplasms 9 Fanconi Anemia, Complementation Group D1 9 Squamous Cell Carcinoma of Head and Neck 8 Glioma 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 7 Glioblastoma 7 Colorectal Neoplasms 6 Metastatic Castration-resistant Prostate Cancer 5 Lymphoma, Non-Hodgkin 5 Cholangiocarcinoma 5 Carcinoma, Renal Cell 5 Uterine Cervical Neoplasms 4 Urinary Bladder Neoplasms 4 Solid Tumors 4 Osteosarcoma 4

Interventions

Cisplatin 127 Gemcitabine 71 Radiotherapy, Intensity-Modulated 61 toripalimab 39 Capecitabine 37 Docetaxel 36 Fluorouracil 35 Radiotherapy 24 camrelizumab 23 Drug Therapy 22 nimotuzumab 18 spartalizumab 13 pembrolizumab 13 nedaplatin 12 Chemoradiotherapy 12 sintilimab 11 apatinib 11 Induction Chemotherapy 11 Immune Checkpoint Inhibitors 11 tislelizumab 10 Nivolumab 10 Magnetic Resonance Spectroscopy 10 Specimen Handling 9 Radiation 9 Cetuximab 9 Carboplatin 9 endostar protein 8 Paclitaxel 8 Bevacizumab 8 anlotinib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Nasopharyngeal Carcinoma × olaparib × Clear all

NCT04825990 2026-06-01

POINT

Gruppo Oncologico del Nord-Ovest

Phase 2 Active not recruiting

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡